ALBIREO PHARMA, INC.
ALBIREO PHARMA, INC. (ALBO): 4 pipeline candidates · ~28 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
27.6 months
D/E 2.21 · 0% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for ALBIREO PHARMA, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$272.5M
Quarterly Burn
$29.6M
Runway
27.6 mo
Revenue
$9.8M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| a2342 | Preclinical |
| a3907 | Preclinical |
| bylvay | Phase 3 |
| elobixibat | Approved |
Frequently asked questions
How many drug candidates are in ALBIREO PHARMA, INC.'s pipeline?
ALBIREO PHARMA, INC. (ALBO) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ALBIREO PHARMA, INC.'s lead drug candidate?
ALBIREO PHARMA, INC.'s most advanced tracked candidate is a2342 (Preclinical) for adult viral and liver diseases.
What is ALBIREO PHARMA, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ALBIREO PHARMA, INC. has approximately 27.6 months of cash runway.
Who is the CEO of ALBIREO PHARMA, INC.?
Albireo Pharma is the chief executive officer of ALBIREO PHARMA, INC. (ALBO).
Get the full picture on ALBIREO PHARMA, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.